An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy
Advanced Science · 2025-12 · 12 (46)
DOI: 10.1002/advs.202512744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 26.09.2025. Verfasst von Yufei Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical …. Hauptthemen laut MEDLINE: Probiotics, Quorum Sensing, Colorectal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Project.
Abstract (Originalsprache)
Recent progress in synthetic biology has empowered engineered probiotics to sense tumor‐specific physicochemical signals, thereby facilitating targeted in situ drug delivery. Here, an engineered probiotic consortium capable of integrating multiple tumor microenvironment (TME) signals and orchestrating multi‐therapeutic payloads release through an orthogonal quorum‐sensing system is designed. The probiotic consortium can respond to three characteristic TME parameters, pH, hypoxia, and high‐lactate levels, in order to achieve controlled release of lactate depletion enzyme (LdhA) for metabolic environment improvement and the programmed death ligand 1 (PD‐L1) nanobody for immune checkpoint inhibition. Using the humanized PD‐1 mouse model bearing hPD‐L1 MC38 tumor and the humanized peripheral blood mononuclear cells (PBMC) mouse model bearing HT‐29 tumor, it is demonstrated that this self‐regulating microbial consortium achieves sustained oscillations and significantly suppresses tumor progression. Mechanistic studies reveal that the antitumor efficacy activates CD8 + , CD4 + , and IFN‐γ + T cells, coupled with diminished immunosuppressive Foxp3 + regulatory T cell infiltration. This work advances the development of engineered live biotherapeutic products for cancer therapy and provides a modular platform for microbial consortium‐based precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, 300072, China.
ORCID-Profile: He Huang, Guangbo Kang
Förderung
- National Key Research and Development Project
Zitieren
APA
Guo, Y., Gao, M., Wang, L., Yuan, H., Yin, J., Wu, J., Gao, X., Zhu, Z., Zhang, Y., Wang, Z., Huang, H., & Kang, G. (2025). An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy. Advanced Science, 12(46). https://doi.org/10.1002/advs.202512744
Vancouver
Guo Y, Gao M, Wang L, Yuan H, Yin J, Wu J, et al. An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy. Advanced Science. 2025;12(46). doi:10.1002/advs.202512744
BibTeX
@article{Guo2025,
author = {Guo, Yufei and Gao, Mengxue and Wang, Lina and Yuan, Haibin and Yin, Jianan and Wu, Jiahao and Gao, Xinran and Zhu, Zhixin and Zhang, Yan and Wang, Zichen and Huang, He and Kang, Guangbo},
title = {An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {46},
doi = {10.1002/advs.202512744}
}
EUVIMED